Clinical Trial

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Study acronym: MSTH-CAR002
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Trial Details
NCT Number NCT07162571
Lead Sponsor Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Conditions Acute Lymphobkastic Leukemia, B Cell Lymphoma
Enrollment 17 participants
Start Date 2026-01-01
Primary Completion 2030-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-09